IQWiG rebuffs Gilead's Stribild

Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) said on Monday that Stribild from Gilead Sciences Inc. (NASDAQ:GILD) has a "smaller" benefit than comparator Atripla to treat HIV-1 infection in treatment-naïve adults or adults without mutations associated with resistance to the antiviral agents in the product. IQWiG's assessment notes that pooled data showed that Stribild was associated with more AIDS-defining events than Atripla. Comments are due Oct. 7, with a final assessment from Germany's Federal Joint Committee (G-BA) expected in early December. ...